23andMe has been granted a patent for binding proteins that target human IL-36 cytokines, blocking their signaling pathways. The patent includes specific sequences for anti-IL-36 antibodies. GlobalData’s report on 23andMe gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights 23andMe Holding Co. - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on 23andMe, was a key innovation area identified from patents. 23andMe's grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Anti-il-36 antibody for blocking il-36 cytokine signaling

Source: United States Patent and Trademark Office (USPTO). Credit: 23andMe Holding Co.

A recently granted patent (Publication Number: US11884719B2) discloses an anti-IL-36 antibody with specific amino acid sequences in its light chain variable domain (VL) and heavy chain variable domain (VH). The antibody is designed to bind to hu-IL-36a, hu-IL-36-ß, and/or hu-IL-36-? with high binding affinity, inhibiting intracellular signals stimulated by these interleukins. The antibody also demonstrates the ability to decrease the release of IL-8 from primary human keratinocytes when stimulated by IL-36a, IL-36ß, and/or IL-36?. Furthermore, the patent includes claims for multispecific antibodies with distinct binding specificities for different IL-36 interleukins, as well as compositions comprising the antibody and a pharmaceutically acceptable carrier.

The patent also covers antibodies that exhibit cross-reactivity with IL-36 interleukins in cynomolgus monkeys, highlighting their potential for broader applications. Additionally, the disclosed antibodies are characterized by their ability to decrease intracellular signals stimulated by IL-36a, IL-36ß, or IL-36? by at least 90%, further underscoring their therapeutic potential. The specificity and binding affinity of the antibodies to different IL-36 interleukins, both in human and cynomolgus monkeys, are detailed in the patent claims, emphasizing the precision and versatility of these novel anti-IL-36 antibodies for potential therapeutic interventions targeting IL-36-mediated inflammatory responses.

To know more about GlobalData’s detailed insights on 23andMe, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies